Int J Tuberc Lung Dis. 2005 Apr;9(4):355-61.
Smear microscopy for acid-fast bacilli (AFB) remains the first priority for national tuberculosis programmes (NTPs) in high-prevalence countries. No other established technique offers the same advantages of accuracy, speed, appropriateness and accessibility. Its sensitivity may be reduced in HIV-positive cases or because of technical deficiencies, and it lacks specificity for viable bacilli in follow-up examinations. Its main problem is that it is tedious, necessitating an effective external quality assessment (EQA) system following international guidelines. Operational research is needed to optimise the staining he place of sputum concentration o define t and fluorescence microscopy, to challenge difficult and obsolete strategies and to streamline procedures. Culture is much more difficult to set up and is usually impossible to decentralise. Because of its lower yield and higher costs, its efficiency for case detection in NTPs will lag well behind that in industrialised countries. The technique should only be used as a preliminary to drug susceptibility testing (DST). DST should not be developed to the detriment of the AFB microscopy network and its EQA. It should be used mainly for monitoring drug resistance. Continuous monitoring of resistance in a representative sample of isolates from first-line failure and relapse cases may be more efficient and more accurate than periodic surveys among new cases, and can be used to identify MDR-TB, whose treatment should be standardised, because of considerable risk of error in the laboratory. A specialist service offering molecular techniques may be useful for exceptional cases, but it has no place in the routine work of NTPs.
对于结核病高发国家的国家结核病规划(NTP)而言,抗酸杆菌(AFB)涂片显微镜检查仍是首要任务。没有其他成熟技术能具备同样的准确性、速度、适用性和可及性优势。在HIV阳性病例中或由于技术缺陷,其敏感性可能会降低,并且在后续检查中对活菌缺乏特异性。其主要问题是操作繁琐,因此需要按照国际准则建立有效的外部质量评估(EQA)系统。需要开展运筹学研究以优化染色方法、取代痰液浓缩方法、确定其位置以及荧光显微镜检查,挑战困难和过时的策略并简化程序。培养的建立要困难得多,而且通常无法分散进行。由于其产量较低且成本较高,其在国家结核病规划中用于病例检测的效率将远远落后于工业化国家。该技术仅应用作药物敏感性试验(DST)的初步手段。不应为开展DST而损害AFB显微镜检查网络及其EQA。DST应主要用于监测耐药性。对一线治疗失败和复发病例的代表性分离株样本进行耐药性持续监测可能比在新病例中进行定期调查更有效、更准确,并且可用于识别耐多药结核病(MDR-TB),鉴于实验室存在相当大的误差风险,其治疗应标准化。提供分子技术的专业服务可能对特殊病例有用,但在国家结核病规划的常规工作中没有立足之地。